Core Viewpoint - Veracyte reported strong quarterly earnings, exceeding expectations and showing significant year-over-year growth in both earnings and revenues [1][2]. Financial Performance - The company achieved earnings of $0.53 per share, surpassing the Zacks Consensus Estimate of $0.41 per share, and up from $0.36 per share a year ago, representing an earnings surprise of +30.06% [1]. - Revenues for the quarter reached $140.64 million, exceeding the Zacks Consensus Estimate by 1.41% and up from $118.63 million in the same quarter last year [2]. Market Performance - Veracyte shares have declined approximately 15.2% since the beginning of the year, while the S&P 500 has gained 0.7% [3]. - The company's stock is currently rated Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.34, with projected revenues of $131.36 million, and for the current fiscal year, the EPS estimate is $1.61 on revenues of $577.29 million [7]. - The Medical - Instruments industry, to which Veracyte belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8].

Veracyte (NasdaqGM:VCYT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsJohn Leite - Global Chief Commercial OfficerKyle Mikson - Managing DirectorMarc Stapley - CEOPhillip Febbo - Chief Scientific Officer and Chief Medical OfficerRebecca Chambers - CFOShayla Gorman - Senior Director of Investor RelationsConference Call ParticipantsAndrew Brackmann - AnalystBill Bonello - Senior Research AnalystDoug Schenkel - Managing Director and Senior Research AnalystKeith Hinton - Senior Analys ...

Veracyte (NasdaqGM:VCYT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsJohn Leite - Global Chief Commercial OfficerKyle Mikson - Managing DirectorMarc Stapley - CEOPhillip Febbo - Chief Scientific Officer and Chief Medical OfficerRebecca Chambers - CFOShayla Gorman - Senior Director of Investor RelationsConference Call ParticipantsAndrew Brackmann - AnalystBill Bonello - Senior Research AnalystDoug Schenkel - Managing Director and Senior Research AnalystKeith Hinton - Senior Analys ...

Veracyte (NasdaqGM:VCYT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker12Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shayla Gorman, Senior Director, Investor Relations. Please go ahead.Good afternoon, everyone. Thank you for joining us today for a discussion of our fourth quarter and full year 2025 financial results. With me today are Marc Stapley, Veracyte's Chief Executive Officer, and Rebecca Chambers, ...

Q4 & FY 2025 Earnings Presentation February 25, 2026 © 2026 Veracyte, Inc. All rights reserved. 1 Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2025 and 2026 financial and operating results; our assumptions for future revenue growth; plans and timing of the release of version 2 of our Veracyte tra ...

Revenue Projections - Veracyte expects total revenue for Q4 2025 to be between $138 million and $140 million, with testing revenue between $134 million and $136 million[5]. - For the full year 2025, Veracyte expects total revenue between $515 million and $517 million, with testing revenue between $491 million and $493 million[5]. Testing Volume - The company anticipates testing volume of approximately 45,500 tests for Q4 2025[5]. - The projected testing volume for the full year 2025 is approximately 169,700 tests[5]. Financial Metrics - Veracyte expects an adjusted EBITDA margin of greater than 25% for the full year 2025[5]. - The company is unable to provide an estimate of net income margin for the full year 2025 due to the unavailability of reliable estimates[6]. - Key components affecting net income margin may include stock-based compensation expenses and acquisition-related expenses[6]. Financial Reporting - The preliminary financial results are subject to completion of financial closing procedures and audit adjustments[6]. - Veracyte's audited financial statements for the full year ended December 31, 2025, are not yet available[6]. - The press release regarding these results was issued on January 11, 2026[5].

Core Insights - Veracyte, Inc. is expected to report quarterly earnings on February 25, 2026, with an anticipated EPS of $0.41 and revenue of approximately $135.8 million, driven by its genomic diagnostics tests, Decipher and Afirma [1][5] Financial Performance - In the previous quarter, Veracyte's adjusted EPS was $0.51, exceeding the Zacks Consensus Estimate by 59.38%, and the company has consistently surpassed earnings estimates over the last four quarters with an average surprise of 45.12% [2] - The upcoming Q4 EPS estimate reflects a 13.9% increase from the previous year, with earnings estimates revised upwards by 2% ahead of the announcement [2] Valuation Metrics - Veracyte's financial metrics indicate a high valuation, with a P/E ratio of approximately 94.73, suggesting investors are willing to pay a premium for its earnings [3][5] - The price-to-sales ratio is about 5.82, indicating that investors are paying over five times the company's sales per share [3] - The enterprise value to sales ratio is around 5.27, and the enterprise value to operating cash flow ratio is approximately 24.10 [3] Financial Health - The company's earnings yield is about 1.06%, and it maintains a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing [4] - Veracyte has a strong current ratio of 6.23, suggesting robust liquidity and the ability to cover short-term liabilities [4]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed al ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando, FL Presentation on March 3rd at 8:05 a.m. Eastern Time Leerink Partners Global Health Conference – Miami, FL Fireside chat on March 9th at 10:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by vi. ...

Core Insights - Veracyte, Inc. (VCYT) is set to report its fourth-quarter 2025 results on February 25, with expectations of strong performance based on previous earnings surprises [1][9] Financial Performance - The Zacks Consensus Estimate for revenues is $138.7 million, indicating a 16.9% increase from the previous year [2] - The Zacks Consensus Estimate for EPS is 41 cents, reflecting a 13.9% year-over-year growth [2] - Earnings estimates have increased by 2.5% in the last 30 days, suggesting positive sentiment leading up to the earnings report [3] Business Segments - The core testing business is anticipated to show solid revenue growth, driven by strong volumes in Decipher and Afirma tests [4][9] - Decipher Prostate tests delivered approximately 26,700 tests in the third quarter, marking 14 consecutive quarters of over 25% year-over-year volume growth, a trend expected to continue [5] - Test volumes in the high-risk localized segment are also expected to have increased, supported by ongoing research and clinical adoption [6] Product Insights - Product volume in the third quarter was around 2,200 tests, with a year-over-year revenue growth of 4%, a trend expected to persist [7] - However, management has indicated a decline in product gross margin due to a transition to a contract manufacturing model [7][9] Market Position - VCYT has an Earnings ESP of +7.98% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating earnings estimates [11] - The company is facing challenges in its biopharma revenues and expects lower product gross margins in the fourth quarter due to restructuring efforts [9][10]